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Abstract
Mutations in the MCPH1 (Microcephalin) and ASPM (abnormal spindle-like microcephaly associated) genes cause primary
microcephaly. Both are centrosomal associated proteins involved in mitosis. Microcephalin plays an important role in DNA
damage response and ASPM is required for correct division of proliferative neuro-epithelial cells of the developing brain.
Reduced MCPH1 mRNA expression and ASPM mRNA over-expression have been implicated in the development of human
carcinomas. Epithelial ovarian cancer (EOC) is characterised by highly aneuploid tumours. Previously we have reported low
Microcephalin and high ASPM protein levels and associations with clinico-pathological parameters in malignant cells from
ascitic fluids. To confirm these previous findings on a larger scale Microcephalin and ASPM expression levels and
localisations were evaluated by immunohistochemistry in two cohorts; a training set of 25 samples and a validation set of
322 EOC tissue samples. Results were correlated to the associated histopathological data. In normal ovarian tissues the
Microcephalin nuclear staining pattern was consistently strong. In the cancer tissues, we identified low nuclear
Microcephalin expression in high grade and advanced stage tumours (p,0.0001 and p= 0.0438 respectively). ASPM had
moderate to high nuclear and low to moderate cytoplasmic expression in normal tissue. Cytoplasmic ASPM expression
decreased with tumour grade and stage in the serous subtype of EOC (p = 0.023 and p= 0.011 respectively). Cytoplasmic
ASPM increased with tumour stage in the endometrioid subtype (p = 0.023). Increasing tumour invasiveness (T3) and lymph
node involvement (N1) also correlated with a decrease in cytoplasmic ASPM in EOC (p = 0.02 and p= 0.04 respectively). We
have validated previous findings of deregulated expression of Microcephalin and ASPM in EOC by confirming associations
for low nuclear Microcephalin levels and high cytoplasmic ASPM levels in a larger scale tumour tissue study. Microcephalin
and ASPM may prove useful biomarkers in EOC.
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Introduction
Approximately 225,000 new cases of ovarian cancer were
diagnosed in 2008 worldwide, comprising 4% of all female cancers
[1,2]. The majority of ovarian cancers are epithelial, frequently
present at advanced stages and are associated with high mortality
rates [3]. Therefore, investigating the function and expression of
potential prognostic proteins is essential for the advancement of
our understanding of the molecular pathogenesis of epithelial
ovarian cancer (EOC). This is especially desirable with regards to
the identification of diagnostic biomarkers for patient management
[4].
The MCPH1 and MCPH5 genes encode Microcephalin and the
abnormal spindle-like microcephaly-associated protein (ASPM)
respectively [5,6]. MCPH1 and MCPH5 are two of ten
microcephaly genes identified, which are implicated in autosomal
recessive primary microcephaly (MCPH) [7–13]. Microcephaly is
characterized by reduced foetal brain growth resulting from
mitotic defects during embryonic brain development [14].
Microcephalin is a nuclear and cytoplasmic protein consisting of
835 amino acids. The protein contains three BRCA1 C-terminus
domains (BRCT), one N-terminally located and two in the C-
terminus [5]. Microcephalin is involved in DNA damage response
with a further role as a regulator of chromosome condensation
preventing cells from entering mitosis before DNA replication is
completed [15–17]. Microcephalin is also known as BRIT1
(BRCT-repeat inhibitor of hTERT expression), which was initially
identified as a transcriptional repressor of human telomerase
reverse transcriptase (hTERT), the catalytic subunit of human
telomerase [18]. The ASPM protein consists of 3477 amino acids
[6] organised into a putative N-terminal microtubule binding
domain [19,20], two Calponin homology repeat motifs, over 80
isoleucine-glutamine (IQ) repeats [6,21] which typically bind
calmodulin and a C-terminus consisting of a single Armadillo like
sequence and a region involved in cytokinesis [8,22]. ASPM plays
a role in controlling mitotic spindle function [6,22]. ASPM is
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located at the spindle poles in metaphase and at the nucleus and
centrosome during interphase [6,22–27]. Furthermore, ASPM
localizes to the midbody during cytokinesis, suggesting that it plays
a role in abscission [22,27].
Several lines of evidence indicate that Microcephalin and
ASPM play a role in carcinogenesis. At the DNA level, Rai et al.
reported thatMCPH1 copy number was decreased in 40% (35/87)
of advanced EOC and in 72% (39/54) of breast cancer cases [16].
Similarly, at the mRNA level MCPH1 mRNA was decreased in
63% (19/30) of EOCs [16]. We have reported reduced
Microcephalin protein levels in 29% (93/319) of invasive ductal
breast carcinomas, with Microcephalin expression decreasing with
increasing breast cancer grade. Importantly, Microcephalin was
an independent predictor of overall breast cancer specific survival
[28]. Recently two further small breast cancer studies have
confirmed the association of reduced Microcephalin expression
with tumour progression and prognosis [29,30]. Decreased
Microcephalin expression was also reported in a small prostate
cancer study [16], which suggested that a negative correlation
exists between Microcephalin levels, genomic stability and
chromosomal aberration. Recently inactivation of MCPH1 by
deletion, promoter methylation and mutation was identified in an
oral squamous cell cancer study [31]. This study also showed that
Microcephalin over expression inhibited proliferation, invasion
and anchorage independent growth and tumour growth in nude
mice supporting the tumour suppressor function of Microcephalin
[31].
In contrast, ASPM mRNA levels were increased in tumour and
transformed human cells [26,32]. Increased ASPM mRNA and
protein levels were also identified in glioblastoma multiforme
(GBM), where they were associated with increasing tumour grade
[32,33]. In addition, ASPM mRNA upregulation was identified in
66% (162/247) of hepatocellular carcinomas, an observation
associated with increased invasion, high stage and early tumour
recurrence [34]. Recently upregulation of ASPM correlated with
reduced patient survival has also been identified in pancreatic
cancer [35].
Our recent EOC study determined a correlation between
Microcephalin and ASPM levels with tumour grade and survival
in cell lines and in primary cultures of malignant cells derived from
ovarian ascites samples [36]. In this work we have validated our
original findings in a larger scale study utilising EOC tissue
samples and have investigated the roles of Microcephalin and
ASPM in EOC progression. Our results suggest that Micro-
cephalin and ASPM may be useful biomarkers in EOC
management.
Materials and Methods
Ethics Statement
Appropriate ethical approval was obtained from the Local
Research Ethics Committee of the Leeds Teaching Hospitals NHS
Trust, Leeds, UK, (REC reference 09/H1306/96). All partici-
pants provided written informed consent and all data were
analysed anonymously.
Patient Samples
A cohort of 25 tumour archival, formalin-fixed, paraffin-
embedded (FFPE) blocks were obtained from the histopathology
department of St James’s University Hospital, Leeds and used to
create the training set. The sample set in this cohort represented
four major (most frequently encountered) EOC subtypes (serous,
endometrioid, mucinous and carcinosarcoma) and were predom-
inately grade 3 tumours. All the blocks in this cohort were then
combined into one in-house tissue microarray (TMA). A normal
cohort consisted of 16 ovarian tissue samples taken from either
normal ovary or from normal tissue adjacent to tumour plus 4
normal fallopian tube and 4 normal endometrium samples were
also available.
Another independent cohort of 322 EOC samples was obtained
from Tissue Array Networks and was designated the validation set.
The validation set consisted of 294 different samples of five major
EOC subtypes (serous, endometrioid, adenocarcinoma, mucinous
and clear cell), plus 8 normal ovarian tissues taken from normal
ovary and 20 from normal tissue adjacent to tumour. The 322
cases were represented in 616 cores, with double cores for cancer
cases and a single core for normal tissue. Tissue cores were
0.6 mm in diameter with a thickness of 5 mm. Clinical data (grade,
pathology diagnosis, International Federation of Gynaecology and
Obstetrics (FIGO) staging and TNM staging [37]) were available
for this cohort. The mean age of the 294 patients was 48 years
(range: 19 to 76 years). The results for association with age were
obtained after the data were dichotomized into two groups (.50
and #50). Detailed patient characteristics of the validation set are
summarized in Table 1.
Tissue Microarray Construction
An in-house TMA was constructed from 25 EOC samples at the
Leeds Institute of Cancer and Pathology facility following a
protocol described by Ellis et al [38]. Manual tissue arrayer
punches with a diameter of 0.6 mm (Beecher Instruments, Inc)
were used to create the cores. Tissue cores were selected from the
most representative tumour area in each tumour block after review
of the associated haematoxylin and eosin stained slides by the
specialist gynaecological histopathologist (NW).
Immunohistochemistry Detection of Microcephalin and
ASPM
To optimise the Microcephalin and ASPM staining protocol,
the in house EOC TMA sections were stained using a range of
antibody dilutions and antigen retrieval methods. Microcephalin
and ASPM were stained separately under the same conditions
except for the antibody retrieval and dilution. Slides were
deparaffinised and rehydrated using xylene and ethanol series.
To block hydrogen peroxidase activity, slides were soaked in 3%
H2O2 in methanol. Antigen retrieval was carried out using Vector
antigen retrieval buffer (Vector Laboratories Ltd) in a pressure
cooker for 4 minutes for Microcephalin and 2 minutes for ASPM.
Sections were blocked with 1:10 vector casein solution (Vector
Laboratories) to reduce non-specific staining. On the TMA
sections the rabbit anti-Microcephalin antibody ab2612 (Abcam)
was used at 1/300 and the rabbit anti-N-terminal ASPM antibody
216.1 [36] used at 1/400. The slides were incubated at 4uC
overnight in a humidified chamber. After three washes with TBS
Tween (0.1%) the slides were incubated for 30 minutes at room
temperature with the rabbit/mouse secondary, peroxidase-conju-
gated EnVision polymer (DAKO). After further washes the
reaction was visualized by the addition of 2% diaminobenzine+
Chromogen in DAP substrate buffer for 10 minutes (DAKO).
Sections were counterstained with Mayer’s haematoxylin (VWR
International Ltd). Negative controls, without primary antibody
and positive controls of normal ovarian tissue were included in
each batch of immunohistochemistry.
Microcephalin and ASPM Antibody Validation
In order to determine the staining specificity of the Micro-
cephalin antibody on FFPE samples, an immunizing peptide
Microcephalin and ASPM in Ovarian Cancer
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blocking experiment was performed on EOC tissue sections and
on the 25 core in-house TMA. The antibody was neutralized by
pre-absorption with the BRIT1 peptide ab13737 (Abcam). The
antibody was diluted to its predetermined working concentration
(described above) and incubated with a tenfold excess of peptide
overnight at 4uC before application to the tissue. Tissue sections
with neutralized antibody were compared with corresponding
tissue sections stained with antibody alone.
We had already determined the antibody specificity of the
ASPM antibody 216.1 in previous work by peptide blocking
immunofluorescence experiments [36]. We further confirmed the
staining pattern of the antibody observed in IHC by staining the
same in-house EOC TMA with another antibody (279.3)
generated against the C-terminus of ASPM. Similar staining
results were obtained with both antibodies with only slight
differences between cytoplasmic staining levels.
For further validation of the specificity and sensitivity of the
antibodies and to control for the effects of formalin fixation and
antigen retrieval, MCPH1 and ASPM were knocked down in the
U-2 OS cell line (ATCC, Manassas, VA, USA) by siRNA as
previously described [17,36,22]. After 72 hrs cells were harvested,
pelleted, formalin fixed and suspended in 1% agar then paraffin
embedded and used as controls for antibody validation.
Immunohistochemical Evaluation
All the TMA sections were scanned using the Aperio Scan
Scope slide scanner (Aperio Technologies) at 40x magnification,
using morphometry tools in Imagescope software (Aperio). For
both Microcephalin and ASPM the replicate cores for each sample
were scored for staining intensities of nuclear and cytoplasmic
staining (intensity score, 0 = no staining, 1 = weak staining, 2 =
moderate staining and 3= strong staining) as well as the
proportion of cells with positive nuclear or cytoplasmic staining
within the cores (proportion score). To analyse the Microcephalin
staining the semi-quantitative Allred (quick) 8-unit system was used
[39]. The proportion of positive nuclear or cytoplasmic stained
cells within each core was defined as 0 = no staining, 1 =,1%
staining, 2 = 1–10% staining, 3 = 11–33% staining, 4 = 34–66%
staining, 5 = 67–100% staining. The final score was obtained by
adding the intensity scores to the proportion scores, achieving a
minimum score of 0 and a maximum score of 8. Cases with a score
of 4 or lower were called low, while cases with a score of 5 or 6
were labelled as moderate and samples with a score of 7 or 8 were
considered as expressing high levels of Microcephalin. For data
analysis of ASPM expression a slightly more sensitive data analysis
system was used, in which the staining intensity was multiplied by
the percentage of cells with nuclear or cytoplasmic staining [40].
Thus the lowest score was 0 and the highest 300. Samples with a
score of 0 were called negative, samples with a score of 1–100 low,
samples with a score of 101–200 moderate and samples with a
score of 201–300 were scored as high expression levels. For
discontinuous data analysis all negative and low samples were
designated low and all medium and high samples were designated
high ASPM levels.
Statistical Analysis
The non-parametric Kruskall-Wallis (K-W) and Wilcoxon-
Mann-Whitney (W-M-W) test were used to identify the association
between Microcephalin and ASPM with clinical variables (disease
stage, grade, histology type, metastases, lymph node involvement
and age of patients). All statistical tests were two-sided, and a P#
0.05 values was considered statistically significant.
Results
Microcephalin and ASPM Antibody Characterization
The Microcephalin and ASPM antibodies were initially
optimized for use on paraffin-embedded TMA sections. Immu-
nohistochemistry with these antibodies demonstrated that Micro-
cephalin and ASPM were localized in the nucleus and in the
cytoplasm of both the normal (Figure 1) and EOC tissue samples
(Figure 2). The nuclear Microcephalin staining pattern was
abolished when the antibody was pre-incubated in the presence
of the peptide. However, some uniform low level background
cytoplasmic staining was still present in all cores (Figure S1).
Therefore, we have not included the cytoplasmic Microcephalin
staining in any further analysis.
Table 1. Patients’ characteristics in the validation set.
Malignant cases in the validation set n=294 (%)
Age
Range 19–76
Mean 48
Age distribution
,50 125 (42.5)
$50 169 (57.5)
Tumour grade
G1 63 (25.7)
G2 72 (29.4)
G3 110 (44.9)
G2/G3 7
Data Missing 42
Histological tumour type
Serous adenocarcinoma 209 (71.1)
Mucinous adenocarcinoma 45 (15.3)
Endometrioid adenocarcinoma 12 (4)
Adenocarcinoma 15 (5.1)
Clear cell carcinoma 13 (4.4)
Tumour FIGO stage
I 205 (69.7)
II 42 (14.3)
III 35 (11.9)
IV 12 (4.1)
Tumour TNM stage
Primary tumour invasion (T)
T1 207 (70.4)
T2 59 (20.1)
T3 28 (9.5)
Lymph node status
No regional lymph node metastasis (N0) 256 (87)
Metastasis in 1–3 region lymph node (N1) 36 (12.3)
Regional lymph node cannot be assessed (NX) 2 (0.7)
Distant metastases
No (M0) 282 (95.9)
Yes (M1) 12 (4.1)
doi:10.1371/journal.pone.0097059.t001
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The staining pattern for ASPM antibody 279.3 performed in
parallel to the staining with antibody 216.1 revealed that
cytoplasmic staining was similar for both antibodies. However,
216.1 showed a more pronounced nuclear staining pattern than
279.3 and consequently this antibody was used to stain the EOC
validation set. Results for staining patterns of representative cores
and a summary of the staining results are shown in Figure S2 and
Table S1.
To further confirm the validity of the antibodies to stain
paraffin-embedded tissues, the antibodies were tested on paraffin-
embedded U-2 OS cells with and without siRNA knockdown
for Microcephalin or ASPM. Knockdown cells for both genes
showed very weak staining relative to the control siRNA (Figure
S3).
Figure 1. Immunohistochemical analysis of Microcephalin and ASPM in normal tissue samples. Normal ovarian epithelium
demonstrating strong Microcephalin expression in both the nuclei and cytoplasm (A & D) and strong nuclear and moderate cytoplasmic ASPM
expression (G & J). Normal Fallopian tube demonstrating heterogeneous moderate nuclear and weak cytoplasmic Microcephalin staining (B & E) and
ASPM staining demonstrating strong nuclear and moderate cytoplasmic expression (H & K). Normal Endometrium showing heterogeneous strong
nuclear and cytoplasmic Microcephalin staining (C & F) and strong nuclear and weak cytoplasmic ASPM staining (I & L). All images are x15
magnification.
doi:10.1371/journal.pone.0097059.g001
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Microcephalin Expression in Normal and EOC Tissue
Samples
Normal ovarian, endometrium and fallopian tube tissue samples
all revealed strong nuclear Microcephalin staining. The majority
(90%) of normal ovarian epithelial cells demonstrated positive
Microcephalin staining while this was slightly lower (70–80%) in
the endometrium and fallopian tube samples (Figure 1A–F).
Initially, the expression of Microcephalin was evaluated in the in
house training set TMA. Dichotomous analysis in the training set
Figure 2. Immunohistochemical analysis of Microcephalin and ASPM expression in malignant samples. Serous adenocarcinoma TMA
cores showing nuclear and cytoplasmic Microcephalin (A and B) and ASPM expression (C and D) respectively. White arrow shows nuclear staining and
black arrow shows cytoplasmic staining. A and B are 20x, C and D are 40x magnification.
doi:10.1371/journal.pone.0097059.g002
Table 2. Microcephalin nuclear intensity in the training set.
Microcephalin nuclear intensity
N=22 Low Moderate
(%) (%) (%)
Tumour grade
G1 1 (4) 1 (100) 0 (0)
G2 5 (23) 4 (80) 1 (20)
G3 16 (73) 11 (69) 5 (31)
Histological tumour type
Serous adenocarcinoma 11 (50) 8 (73) 3 (27)
Mucinous adenocarcinoma 2 (9) 2 (100) 0 (0)
Endometrioid adenocarcinoma 8 (36) 5 (62.5) 3 (37.5)
Carcinosarcoma 1 (4) 1 (100) 0 (0)
doi:10.1371/journal.pone.0097059.t002
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demonstrated loss of Microcephalin expression in 16/22 (73%)
cases (Table 2). In the EOC validation set, low Microcephalin
expression was identified in 30% (89/294) of EOC samples
(Table 3). Since we were particularly interested in Microcephalin
expression levels and its association with tumourigenesis, we
examined our IHC data to identify potential correlations with the
associated clinical data. Interestingly, dichotomous analysis in the
training set demonstrated loss of Microcephalin expression in
grade 3 EOC tumours (Table 2). This finding was confirmed in
the validation set with low nuclear staining mainly found in the
grade 3 tumours (48%; 53/110 p,0.0001). In low-grade tumours,
moderate or high nuclear staining was observed (p,0.0001)
(Figure 3). Microcephalin nuclear expression also declined with
increased tumour stage (p=0.0438) (Figure 4). Patients over 50
years of age demonstrated lower nuclear Microcephalin levels
(Table 3), but the difference was not statistically significant
(p=0.0581). No significant changes in Microcephalin expression
were identified between different pathological subtypes (p=0.486)
(Table 3). However, the majority (8/10, 80%) of clear cell
carcinomas displayed moderate or strong Microcephalin immu-
nostaining. This may reflect the fact that 6/8 of these cases were
stage I and or that the different subtypes of EOC follow different
molecular pathways. We also noted high rates of loss of
Microcephalin in serous and mucinous adenocarcinoma (68/
207, 33% and 15/44, 34%, respectively, Table 3). Figure 5A–D
demonstrates the expression of Microcephalin in the different
epithelial ovarian cancer subtypes.
Table 3. Correlation of nuclear Microcephalin expression with clinicopathological data in the EOC validation set.
Malignant cases in the validation set Microcephalin nuclear intensity Statistical analysis
Samples Low Moderate High P value
N=294 (%) Valid n (%) (%) (%)
Age distribution
,50 125 (42.5) 119 43 (36) 56 (47) 20 (17)
$50 169 (57.5) 159 46 (29) 70 (44) 43 (27) 0.0581
Histological tumour type
Serous adenocarcinoma 209 (71.1) 208 69 (33) 90 (43) 49 (24)
Mucinous adenocarcinoma 45 (15.3) 44 15 (34) 21 (45) 8 (18)
Endometrioid adenocarcinoma 12 (4.1) 11 3 (27) 7 (46) 1 (9) 0.486
Adenocarcinoma 15 (5.1) 5 0 (0) 4 (80) 1 (20)
Clear cell carcinoma 13 (4.4) 10 2 (20) 4 (40) 4 (40)
Tumour grade
G1 63 (25.7) 61 14 (23) 28 (46) 19 (31)
G2 72 (29.3) 72 16 (22) 38 (53) 18 (25)
G3 110 (45) 110 53 (48) 41 (37) 16 (15) ,0.0001
G2/G3 7 7 1 4 2
Data Missing 42 28 5 15 8
Tumour FIGO stage
I 205 (69.7) 196 56 (29) 92 (47) 48 (24)
II 42 (14.3) 38 12 (32) 19 (50) 7 (18) 0.0438
III 35 (11.9) 34 16 (47) 13 (38) 5 (15)
IV 12 (4.1) 10 5 (50) 2 (20) 3 (30)
Tumour TNM stage
Primary tumour invasion (T)
T1 208 (70.7) 199 57 (28.7) 93 (46.7) 49 (24.6) T1 vs. T2 vs. T3 0.144
T2 59 (20.1) 54 21 (38.9) 25 (46.3) 8 (14.8) Control vs. T1 0.0021
T3 27 (9.2) 25 11 (44) 8 (32) 6 (24) Control vs. T2 0.0009
Lymph node status
N0 257 (87) 242 74 (30) 112 (47) 56 (23)
N1 36 (12.3) 35 15 (43) 14 (40) 6 (17) 0.1162
NX 1 (0.7) 1 0 (0) 0 (0) 1 (100)
Distant metastases
No (M0) 282 (95.9) 268 84 (31.5) 124 (46) 60 (22.5) 0.5251
Yes (M1) 12 (4.1) 10 5 (50) 2 (20) 3 (30)
P#0.05 is significant and are shown in bold.
doi:10.1371/journal.pone.0097059.t003
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ASPM Expression in Normal and EOC Tissue Samples
The normal ovarian epithelium, endometrium and fallopian
tube showed variable ASPM expression, with moderate to high
nuclear expression and low to moderate cytoplasmic ASPM
staining (Figure 1G–L). The ASPM expression pattern in EOC
was determined by immunohistochemistry using the training set of
25 paraffin-embedded sections. The staining pattern in these
tumour samples was nuclear and cytoplasmic. In the training set,
high nuclear staining (combined medium and strong staining
pattern) was observed in high-grade tumours (9/14, 64.3%),
whereas high cytoplasmic ASPM was present in all cores
regardless of grade. However, subdividing staining into weak,
Figure 3. Microcephalin expression in EOC validation set
samples correlates with tumour grade. Ai. Normal ovarian
epithelial tissue with high Microcephalin expression. Aii-iv. Adenocar-
cinoma TMA cores showing strong Microcephalin expression in a low
grade tumour (Aii), moderate Microcephalin in grade 2 (Aiii) and low
levels of nuclear Microcephalin expression in a high grade tumour (Aiv).
All images are 40x magnification. B. The correlation between nuclear
Microcephalin expression decreases with increasing tumor grade (p,
0.0001 using an ANOVA test).
doi:10.1371/journal.pone.0097059.g003
Figure 4. Microcephalin expression in EOC validation set
samples inversely correlates with tumour stage. Ai. Normal
ovarian epithelial tissue demonstrating high Microcephalin expression
levels. Aii-4iv Adenocarcinoma TMA cores showing strong Microcepha-
lin (Aii), moderate Microcephalin (Aiii) and low levels of nuclear
Microcephalin expression (Aiv) in stage 1, 2 and 3 tumours respectively.
All images are 40x magnification. B. Weak Microcephalin levels in the
nucleus are associated with advanced tumour stage (p= 0.0438 using
an ANOVA test).
doi:10.1371/journal.pone.0097059.g004
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medium and strong revealed an increase in high nuclear ASPM
levels in the grade 3 tumours. Overall, the proportion of positive
nuclear staining was categorized into strong (21%, 4/19), medium
(31.6%, 6/19) and weak (47.4%, 9/19) (Table 4). Analysis showed
that 10.5% (2/19) of samples had strong cytoplasmic staining and
89.5% (17/19) had moderate cytoplasmic staining. Low cytoplas-
mic staining was not observed. Further analysis revealed a trend
for increased cytoplasmic and nuclear ASPM staining with grade
(Table 4).
In the validation set nuclear and cytoplasmic staining was also
observed. The staining patterns differed between tumour samples
and examples of low and high ASPM expression are shown in
Figure 6A–D. No statistically significant associations were
identified between nuclear ASPM expression and the clinical
data. Though, interestingly 52/294 (18%) of cases showed high
nuclear ASPM expression, which increased with grade. Analysis of
the validation set using continuous data analysis revealed low
levels of cytoplasmic ASPM significantly correlated with high-
grade tumours in the serous subtype (p,0.001) (Figure 7A).
Discontinuous analysis revealed that there was a significant
correlation between low cytoplasmic ASPM and high tumour
grade (p = 0.0138) and also tumour FIGO stage (p= 0.032)
(Table 5). Further analysis of the discontinuous data by subdivision
into cancer subtypes revealed that in addition to the correlation of
low cytoplasmic ASPM with high tumour grade, there was also an
association of decreasing ASPM cytoplasmic levels with increasing
grade in the serous subtype (p,0.0001) (Figure 7B) and an
increase of ASPM expression levels with increasing tumour stage
in the endometrioid subtype (p = 0.0229) (Figure 7C). A significant
association between decreasing cytoplasmic ASPM staining and
stage in the serous subtype was also identified (p = 0.0017)
(Figure 7D). A significant association between cytoplasmic ASPM
levels and patient age was not observed (Table 5).
Relationship Between Histopathological Staging (FIGO
and TNM staging) and Microcephalin and ASPM
expression
In the validation set Microcephalin was found to decrease with
increasing tumour stage when using the FIGO staging system
(p=0.0438) (Table 3). Similarly ASPM cytoplasmic staining
decreased with increasing tumour stage when using the FIGO
staging system (p=0.0032) (Table 5). Microcephalin and ASPM
expression levels were further assessed in the context of disease
severity as determined by the level of tumour invasiveness (T1, T2
and T3). Nuclear Microcephalin expression levels decreased even
if the tumour was limited to the ovaries (T1; p = 0.0021). When
comparing Microcephalin expression in T2 with the control
group, the result became more significant (p = 0.0009). However,
there was no significant difference in Microcephalin expression
when samples in the T1, T2 and T3 groups were compared to
each other. Furthermore, Microcephalin expression did not
significantly correlate with regional lymph node involvement
(p = 0.1162) or distant metastasis (p = 0.5251) (Table 3).
Figure 5. Microcephalin expression in different EOC subtypes. A. Clear cell carcinoma and B. Endometrioid adenocarcinoma both showing
strong Microcephalin expression. C. Mucinous adenocarcinoma and D. Serous adenocarcinoma both presenting weak Microcephalin expression. All
images are x40 magnification.
doi:10.1371/journal.pone.0097059.g005
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For ASPM, an association between cytoplasmic staining levels
and tumour invasiveness was identified. High cytoplasmic ASPM
levels were found at T1, which decreased significantly with T2 and
T3 (p = 0.0198) (Figure 7E). High cytoplasmic ASPM also
correlated with no lymph node involvement (N0) and it decreased
with lymph node involvement (N1) (p = 0.04) (Figure 7F) (Table 5).
Discussion
EOC is frequently first diagnosed at an advanced stage due to
the lack of symptoms and reliable early detection methods.
Consequently the identification of diagnostic and prognostic
biomarkers for EOC is of major clinical importance. In this study
we investigated the expression of two MCPH proteins, Micro-
cephalin and ASPM, in EOC tumour tissue samples. EOC
displays a high degree of aneuploidy. DNA damage response
proteins are a vital defence against genomic instability and defects
in these proteins may lead to cancer. Microcephalin has a known
role in DNA repair and ASPM for spindle function during mitosis.
The purpose of this study was to determine whether Micro-
cephalin and ASPM expression are associated with clinicopatho-
logical parameters in patients with EOC. Both proteins had been
shown to be deregulated in other cancers in a manner that was
associated with tumour progression [16,28–30,36].
Recently we reported an association of Microcephalin and
ASPM levels in malignant cells derived from ascitic fluids from
EOC patients with various clinic-pathological parameters [36]. In
the present, larger scale study, nuclear and/or cytoplasmic
Microcephalin staining was identified in the tumour cells. Our
results in the training set revealed a reduction in nuclear
Microcephalin expression in 73% (16/22) of EOC tumours; this
percentage was reduced to 30% (89/294) in the validation set.
This difference between the two cohorts potentially reflects the
higher number of grade 3 cases in the training set (73%; 16/22)
compared to the validation set (37%; 110/294). In this study low
Microcephalin expression was identified in high grade and
advanced stage tumours (p,0.0001 and p= 0.0438 respectively).
These findings match our previous study on ovarian ascites
samples that indicated that Microcephalin expression was reduced
in cell cultures derived from ascites of EOC patients with
advanced tumours [36]. Our results are compatible with studies
that reporting reduced MCPH1 DNA copy number in 72% (39/
54) of breast cancers [16] and to our own findings of reduced
Microcephalin expression in 93/319 (29%) of breast cancer
samples, particularly in the higher grade tumours [28].
Previously, we identified a correlation between the abnormal
localization of Microcephalin with tumour grade in primary
cultures of malignant cells derived from ascitic fluids from patients
with EOC. In these cells, cytoplasmic Microcephalin increased
with tumour grade. We suggested that might be because of
MCPH1 deletion mutations in the C-terminal BRCT domains that
have previously been shown to result in Microcephalin moving
from a nuclear to cytoplasmic localization similar to BRCA1
[41,42,43]. A recent study characterizing different MCPH1 splice
variants reported mutation or deletion of nuclear localization
signals within the MCPH1 gene resulted in a localization change
from nuclear to cytoplasmic [43]. In this study weak to moderate
Microcephalin cytoplasmic staining was seen in all grade 2 and 3
samples and increased cytoplasmic Microcephalin expression was
associated with increased tumour grade (p=0.0051). However due
to non-specific background cytoplasmic staining observed in the
blocking peptide experiment, cytoplasmic expression was not
included here.T
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Our findings of reduced expression of the DNA repair protein
Microcephalin in high grade tumours but few low grade tumours
is consistent with the molecular characteristics of these different
tumour types. Loss of DNA repair function e.g. BRCA genes
leading to chromosomal instability and a complex genome is
common in high grade cancers. In contrast to low grade tumours
which do not tend to display chromosomal instability and BRCA
mutations.
Similarly to Microcephalin expression, in this study we
recapitulated our recent findings on cytoplasmic ASPM levels
and tumour grade. In primary cultures of malignant cells derived
from ovarian ascites samples we had determined that cytoplasmic
ASPM levels decreased with tumour grade. In this study we were
able to verify this result in the serous subtype in the large-scale
validation set of EOC tumour samples. In addition we were able to
determine associations of cytoplasmic ASPM levels with disease
stage, where high cytoplasmic ASPM levels were predominantly
found in low stages (1 and 2) in the serous subtype and an increase
of cytoplasmic ASPM levels with stage in the endometrioid
subtype. It has been suggested that the different subtypes of EOC
follow different molecular pathways and this may be represented
in our results. Cytoplasmic ASPM levels were also found to be
associated with tumour invasiveness with highest cytoplasmic
ASPM levels found only when the tumour remained confined to
the ovaries (T1). This may indicate that high levels of cytoplasmic
ASPM are important for tumourigenesis but not for tumour
progression.
Although cytoplasmic and nuclear locations of ASPM in other
tumour types have been noted in the literature [32,44] so far there
is little information about the role of this differential location of
ASPM, especially with regards to EOC. It has been demonstrated
that there are at least four isoforms of ASPM with potentially
different functions [24]. Our ASPM antibody should detect
expression of full length and ASPM variant 1 [24], however little
research has been performed on the relative cellular distribution or
relative expression levels of the ASPM isoforms. In EOC tumours,
ASPM over expression and/or the increase in ASPM cytoplasmic
localisation may be explained as an increase in relative expression
of only one of the two detectable ASPM isoforms, or of a novel
isoform and the change in expression of the fully functional
wtASPM protein in relation to the partially functional ASPM
isoform may have an affect on cancer progression.
Interestingly, our findings of different cytoplasmic ASPM
expression levels and associations with tumour stage among two
subtypes reflect recent findings in the literature. For example,
Ko¨bel et al, 2008 [45], stated that a study of 21 candidate
biomarkers for EOC revealed a varied association of biomarker
expression with subtypes and they argued that each subtype within
a cohort should be analyzed discretely. In our case the associations
of ASPM expression levels especially in the serous and endome-
trioid subtypes may hint at distinct roles of ASPM in these cancer
Figure 6. Variation of ASPM nuclear and cytoplasmic staining in validation set EOC tissue samples. A and B. TMA core with low nuclear
and cytoplasmic ASPM expression. C and D. TMA core with high nuclear and cytoplasmic ASPM expression. White arrow indicates nuclear stain, black
arrow indicates cytoplasmic stain. A and C are 6.2x and B, D are 20x magnification respectively.
doi:10.1371/journal.pone.0097059.g006
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types. In the case of serous EOC ASPM may play a role especially
in the tumorigenesis of high grade serous carcinomas which are
characterised by high chromosomal instabilty and aneuploidy. In
endometrioid cancers this role may be different as most of our
samples were low grade and there seemed to be an increase in
cytoplasmic ASPM with stage. It will be interesting to confirm our
findings in a larger data set of the less represented EOC subtypes.
Our finding support the notion that EOC is not a single disease
entity but should be managed as several distinct disease entities.
In summary, in this study we investigated the potential use of
Microcephalin and ASPM expression in clinical practice in EOC
in a large scale study. We conclude that deregulation of
Microcephalin and ASPM expression is significantly associated
with tumourigenesis. The results from this study warrant the
Figure 7. Cytoplasmic ASPM levels correlate with various clinic-pathological parameters in EOC. A. Cytoplasmic ASPM levels decrease
with grade in serous EOC (continuous data, p,0.0001). B. Cytoplasmic ASPM levels decrease with tumour grade in the serous subtype (discontinuous
data, p = 0.0239). C. Cytoplasmic ASPM levels increase with disease stage in endometrioid EOC (discontinuous data, p = 0.0229). D. Cytoplasmic ASPM
levels decrease with disease stage in the serous subtype (discontinuous data, p = 0.0017). E. Cytoplasmic ASPM levels decrease with tumour invasion
(discontinuous data, p = 0.02). F. High cytoplasmic ASPM levels correlate with no lymph node involvement (p = 0.04). All data analysed using an
ANOVA test.
doi:10.1371/journal.pone.0097059.g007
Table 5. Correlation of cytoplasmic ASPM expression with clinicopathological data in the EOC validation set.
Malignant cases in the validation set Statistical analysis
Samples Low High P value
N=294 (%) Valid n (%) (%)
Age distribution
,50 155 (52.7) 155 30 (19.3) 125 (80.7)
$50 139 (47.3) 139 36 (25.9) 103 (74.1) 0.0763
Histological tumour type
Serous adenocarcinoma 209 (71.1) 198 33 (16.8) 165 (83.3)
Mucinous adenocarcinoma 45 (15.3) 44 15 (34) 24 (57.2)
Endometrioid adenocarcinoma 12 (4.1) 11 3 (27) 6 (54.6) 0.1643
Adenocarcinoma 15 (5.1) 5 0 (0) 7 (46.7)
Clear cell carcinoma 13 (4.4) 10 2 (20) 4 (46.2)
Tumour grade
G1 61 (24.5) 61 8 (13.1) 53 (86.9)
G2 78 (31.3) 78 18 (23.1) 60 (76.9)
G3 110 (44.2) 110 26 (23.6) 84 (76.4) ,0.0138
G2/G3 7 5 0 (0) 5 (100)
Data Missing 38 37 19 (51.4) 18 (48.7)
Tumour FIGO stage
I 205 (69.7) 196 40 (20.5) 155 (79.5)
II 42 (14.3) 37 6 (16.2) 31 (83.7) 0.0032
III 35 (11.9) 34 9 (26.5) 25 (73.5)
IV 12 (4.1) 10 3 (30) 7 (70)
Tumour TNM stage
Primary tumour invasion (T)
T1 208 (70.7) 205 43 (21) 162 (79) T1 vs. T2 vs. T3 0.0198
T2 59 (20.1) 59 13 (22) 46 (78)
T3 27 (9.2) 27 8 (32.1) 19 (67.9)
Lymph node status
N0 257 (87) 254 57 (22.4) 197 (77.6)
N1 36 (12.3) 35 9 (25.7) 26 (74.3) 0.0401
NX 1 (0.7) 1 0 (0) 1 (100)
Distant metastases
No (M0) 282 (95.9) 280 4 (33.3) 218 (77.2) 0.1568
Yes (M1) 12 (4.1) 12 62 (22.1) 8 (66.7)
P#0.05 is significant and are shown in bold.
doi:10.1371/journal.pone.0097059.t005
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further investigation of Microcephalin and ASPM as potential
biomarkers in EOC.
Supporting Information
Figure S1 Characterization of the anti-Microcephalin
antibody. Immunohistochemical staining of Microcephalin in
the absence (A and C) and presence (B and D) of the peptide the
antibody was raised against illustrating, low non-specific cytoplas-
mic background staining. A and B are 40x magnification, C and D
are 10x magnification.
(TIF)
Figure S2 Comparison of two different ASPM antibod-
ies. The staining patterns of the N-terminal 216.1 and C-terminal
279.3 ASPM antibodies 216.1 (A and C) and 279.3 (B and D)
revealed identical cytoplasmic and nuclear localization and
relative protein expression levels. A and B TMA core obtained
for the same patient sample showing low level ASPM expression.
C and D TMA core obtained for the same patient showing high
ASPM expression. All images are 6.2x magnification.
(TIF)
Figure S3 Conformation of antibody specificity by
siRNA knockdown in U-2 0S cells. Immunohistochemistry
analysis of paraffin embedded U-2 0S cells after siRNA
knockdown stained with anti Microcephalin (A and B) or ASPM
(C and D) antibodies respectively. Cells transfected with scrambled
control siRNA showed high Microcephalin (A) and ASPM (C)
expression respectively. Cells transfected with MCPH1 (B) or
ASPM (D) siRNA showed low expression. All images are x40
magnification.
(TIF)
Table S1 Analysis of the staining intensities of two
different ASPM antibodies 216.1 and 279.3 performed on
the training set TMA.
(DOCX)
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